Expression and Functional Pathway Analysis of Nuclear Receptor NR2F2 in Ovarian Cancer
Open Access
- 1 July 2013
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 98 (7) , E1152-E1162
Abstract
Context: Recent evidence implicates the orphan nuclear receptor, nuclear receptor subfamily 2, group F, member 2 (NR2F2; chicken ovalbumin upstream promoter-transcription factor II) as both a master regulator of angiogenesis and an oncogene in prostate and other human cancers. Objective: The objective of the study was to determine whether NR2F2 plays a role in ovarian cancer and dissect its potential mechanisms of action. Design, Setting, and Patients: We examined NR2F2 expression in healthy ovary and ovarian cancers using quantitative PCR and immunohistochemistry. NR2F2 expression was targeted in established ovarian cancer cell lines to assess the impact of dysregulated NR2F2 expression in the epithelial compartment of ovarian cancers. Results: Our results indicate that NR2F2 is robustly expressed in the stroma of healthy ovary with little or no expression in epithelia lining the ovarian surface, clefts, or crypts. This pattern of NR2F2 expression was markedly disrupted in ovarian cancers, in which decreased levels of stromal expression and ectopic epithelial expression were frequently observed. Ovarian cancers with the most disrupted patterns of NR2F2 were associated with significantly shorter disease-free interval by Kaplan-Meier analysis. Targeting NR2F2 expression in established ovarian cancer cell lines enhanced apoptosis and increased proliferation. In addition, we found that NR2F2 regulates the expression of NEK2, RAI14, and multiple other genes involved in the cell cycle, suggesting potential pathways by which dysregulated expression of NR2F2 impacts ovarian cancer. Conclusions: These results uncover novel roles for NR2F2 in ovarian cancer and point to a unique scenario in which a single nuclear receptor plays potentially distinct roles in the stromal and epithelial compartments of the same tissue.Keywords
This publication has 39 references indexed in Scilit:
- Nek2A contributes to tumorigenic growth and possibly functions as potential therapeutic target for human breast cancerJournal of Cellular Biochemistry, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Functional MicroRNA Involved in EndometriosisMolecular Endocrinology, 2011
- P450Arom induction in isolated control endometrial cells by peritoneal fluid from women with endometriosisFertility and Sterility, 2010
- Nuclear Receptor COUP-TFII Controls Pancreatic Islet Tumor Angiogenesis by Regulating Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2 SignalingCancer Research, 2010
- The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2Oncogene, 2010
- Suppression of ERα Activity by COUP-TFII Is Essential for Successful Implantation and DecidualizationMolecular Endocrinology, 2010
- Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatinCancer Science, 2010
- Molecular Profiling Uncovers a p53-Associated Role for MicroRNA-31 in Inhibiting the Proliferation of Serous Ovarian Carcinomas and Other CancersCancer Research, 2010
- COUP-TFII regulates tumor growth and metastasis by modulating tumor angiogenesisProceedings of the National Academy of Sciences, 2010